Safety of propofol use in children and adolescents: A disproportionality analysis of the Food and Drug Administration adverse event reporting system (FAERS)

被引：0
|
作者：
Li, Hailong [1 ]
Bo, Zhenyan [1 ]
Zhang, Lingli [1 ]
机构：
[1] Sichuan Univ, West China Univ Hosp 2, Dept Pharm, Chengdu, Sichuan, Peoples R China
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2021年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：334 / 335
页数：2
相关论文
共 50 条
  • [41] Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Xiong, Xiaomei
    Zhang, Xiuwen
    Li, Xiaoxia
    Huang, Taomin
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (11) : 1447 - 1452
  • [42] Pharmacovigilance Analysis of the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) Events for Daprodustat
    Bell, Abraham
    Maddineni, Gautam
    Milutinovic, Stefan
    Bell, Isaac
    Oliveira, Meloney
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [43] Newer Antiseizure Medications and Suicidality: Analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) Database
    Leppien, Emily E.
    Doughty, Bennett J.
    Hurd, Karyssa L.
    Strong, Keira N.
    Piper, Brian J.
    McCall, Kenneth L.
    CLINICAL DRUG INVESTIGATION, 2023, 43 (06) : 393 - 399
  • [44] Association of antidepressants with cataracts and glaucoma: a disproportionality analysis using the reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS) pharmacovigilance database
    Le, Gia Han
    Wong, Sabrina
    Kwan, Angela T. H.
    Rosenblat, Joshua D.
    Mansur, Rodrigo B.
    Teopiz, Kayla M.
    Ho, Roger
    Rhee, Taeho Greg
    Vinberg, Maj
    Cao, Bing
    Liao, Sonya
    Mcintyre, Roger S.
    CNS SPECTRUMS, 2024, 29 (06) : 682 - 696
  • [45] Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
    Liang, Yankun
    Ma, Lin
    Wang, Yuting
    Zheng, Jingping
    Su, Ling
    Lyu, Jun
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [46] Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the US Food and Drug Administration Adverse Event Reporting System (FAERS)
    Rahman, Md. Motiur
    Alatawi, Yasser
    Cheng, Ning
    Qian, Jingjing
    Plotkina, Annya V.
    Peissig, Peggy L.
    Berg, Richard L.
    Page, David
    Hansen, Richard A.
    EPILEPSY RESEARCH, 2017, 135 : 71 - 78
  • [47] Empirical estimation of under-reporting in the US Food and Drug Administration Adverse Event Reporting System (FAERS)
    Alatawi, Yasser M.
    Hansen, Richard A.
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (07) : 761 - 767
  • [48] Post authorization safety study of pitavastatin: A disproportionality analysis in FDA adverse event reporting system database (FAERS)
    Viswam, Subeesh Kulangara
    Reddy, Neha
    Mandepudi, Alekhya
    Padmanabuni, Gayathri
    Sharma, Vasista
    Gouri, Nair
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 473 - 473
  • [49] Evaluating drug withdrawal syndrome risks through food and drug administration adverse event reporting system: a comprehensive disproportionality analysis
    Zhang, Zheng
    Yang, Qianzhi
    Chen, Minghao
    Yang, Wah
    Wang, Yuping
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [50] Comparisons of adverse event reporting for colistin versus polymyxin B using the US Food and Drug Administration Adverse Event Reporting System (FAERS)
    Cong Bang Truong
    Durham, Spencer H.
    Qian, Jingjing
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (05) : 603 - 609
12345